Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it
Maintaining weight loss after medication ends is a difficult transition, prompting researchers to test two practical support options…
Structured support may slow weight regain after stopping GLP-1 drugs
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for obesity, but discontinuation is common due to cost, insurance…
GLP-1 drugs may influence chronic pain through gut-brain and immune pathways
From microbial metabolites and spinal microglia to osteoarthritis and headache trials, researchers map how GLP-1 signaling intersects with…
GLP-1 drugs and SGLT-2 inhibitors linked to slower kidney decline
The diabetes drugs glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs may also…
Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected
Researchers compared two widely used incretin therapies in more than 16,000 matched adults with asthma and type 2…
GLP-1 drugs appear psychiatrically safe, but one finding still raises questions
With millions of patients now taking GLP-1 drugs, researchers examined whether concerns about depression and suicidality are supported…
GLP-1s not a ‘lifestyle product’ – The Star
GLP-1s not a ‘lifestyle product’ The StarCalls to poison centers skyrocket amid rise in use of GLP-1 drugs, experts…
Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Semaglutide and tirzepatide linked to fewer alcohol-related hospital visits
A large US health-record study suggests newer GLP-1 drugs may reduce alcohol-related acute-care visits, but the findings remain…
GLP-1 receptor agonists may increase hair loss risk
Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased…
Popular diabetes drugs do not alter the risk of developing a blinding eye condition
An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – a type of…
Nearly one in 10 Britons use or want weight-loss medication
A nationally representative survey estimates that millions of adults in Great Britain have already used GLP-1-based weight-loss medicines…